This website is best viewed using the vertical display on your mobile device.

This website is best viewed using the horizontal display on your tablet device.

INDICATIONS

Considering ELIQUIS

ELIQUIS IS
FDA-APPROVED

In a clinical trial of patients with AFib not caused by a heart valve problem,

ELIQUIS WAS PROVEN BETTER THAN WARFARIN:

ELIQUIS and other blood thinners increase the risk of bleeding, which can be serious, and rarely may lead to death. In another trial compared to aspirin, ELIQUIS had a modest increase in major bleeding.*

If you’re taking warfarin, consider talking to your doctor about ELIQUIS for both these reasons: ELIQUIS was proven effective to reduce the risk of stroke due to atrial fibrillation (AFib) not caused by a heart valve problem. Plus, ELIQUIS had significantly less major bleeding* than warfarin.

*Major bleeding included noticeable bleeding with at least 1 of the following—a transfusion of 2 or more units of blood; bleeding that occurred in the brain, spine, eye, inside the abdomen, around the heart, in a joint, or in a muscle, leading to damage; or fatal bleeding.

Questions about AFib,
stroke risk, and blood thinners?
Learn more about AFib & Stroke Risk.

BASED ON EXTENSIVE CLINICAL RESEARCH

ELIQUIS WAS PROVEN EFFECTIVE

ELIQUIS was studied in 2 clinical trials to evaluate stroke risk reduction in patients
with AFib not caused by a heart valve problem. Clinical trial results are important because they can help doctors consider and choose the right treatment for you based on their efficacy and safety results.

~24,000

PATIENTS PARTICIPATED IN 2 STUDIES

>11,000

PATIENTS TOOK ELIQUIS

CLINICAL TRIALS

TRIAL 1

Compared ELIQUIS to warfarin in patients with AFib not caused by
a heart valve problem. This group also had at least one additional risk factor for stroke (a prior stroke, age 75 or older, diabetes, heart failure, high blood pressure).

TRIAL 2

Compared ELIQUIS to aspirin in patients with AFib not caused by a heart valve problem who were not suitable for treatment with warfarin. This group also had at least one additional risk factor for stroke (a prior stroke, age 75 or older, diabetes, heart failure, or peripheral artery disease).

Based on the results of these clinical trials, ELIQUIS was approved to reduce the risk
of stroke and blood clots in patients with AFib not caused by a heart valve problem.

In trial 1, ELIQUIS had significantly less major bleeding than warfarin. In trial 2, ELIQUIS had a modest increase in major bleeding compared to aspirin.

“

When I asked my doctor if I needed to keep taking a blood thinner, we spoke about the clinical trial results and how ELIQUIS reduces stroke risk for patients with AFib not caused by a heart valve problem. It was good for me to see this information for myself.

BITSY, A REAL ELIQUIS PATIENT

Bitsy was diagnosed with AFib not caused by a heart valve problem.
She was compensated for her time and expenses.

”

SELECTED IMPORTANT SAFETY INFORMATION

For people taking ELIQUIS^® (apixaban) for atrial fibrillation: Do not stop taking ELIQUIS without talking to the doctor who prescribed it for you. Stopping ELIQUIS increases your risk of having a stroke.

ELIQUIS may need to be stopped prior to surgery or a medical or dental procedure. Your doctor will tell you when you should stop taking ELIQUIS and when you may start taking it again. If you have to stop taking ELIQUIS, your doctor may prescribe another medicine to help prevent a blood clot from forming.

ELIQUIS can cause bleeding, which can be serious, and rarely may lead to death. This is because ELIQUIS is a blood thinner medicine that reduces blood clotting. While taking ELIQUIS, you may bruise more easily and it may take longer than usual for any bleeding to stop.

You may have a higher risk of bleeding if you take ELIQUIS and take other medicines that increase your risk of bleeding, such as aspirin, nonsteroidal anti-inflammatory drugs (called NSAIDs), warfarin, heparin, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), and other medicines to help prevent or treat blood clots. Tell your doctor about all of the medicines you take, including any over-the-counter medicines, vitamins, and herbal supplements.

Please read additional Important Safety Information, including Boxed WARNINGS below.

More Reasons to Consider ELIQUIS

It's important for you and your doctor to discuss your lifestyle when choosing a blood thinner.
Here are some other things to know about taking ELIQUIS.

With ELIQUIS there are no known dietary restrictions or watch-outs for foods like
leafy greens.

Patients taking ELIQUIS do not have to go for routine INR* blood testing.

*International Normalized Ratio

To understand how ELIQUIS compares to warfarin in other areas, be sure to discuss INR blood testing or foods to watch out for with your doctor.

Keep in mind that warfarin and ELIQUIS are both prescription medicines. Only your doctor can decide which blood thinner is right for you.

“

I was resistant, because I know that with warfarin you have to go regularly to have INR blood tests. I told my doctor my concerns and he recommended ELIQUIS, which does not require regular blood testing.

WILLIAM, A REAL ELIQUIS PATIENT

William was diagnosed with AFib not caused
by a heart valve problem.
He was compensated
for his time and expenses.

”

Learn about some
possible side effects of ELIQUIS.

Watch Myra share

share her reaction

to learning she has AFib not
caused by a heart
valve
problem, and how she and
her doctor
chose ELIQUIS
to reduce her risk of stroke.

Myra was compensated
for her time and expenses.

Please see U.S. Full Prescribing Information, including Boxed WARNINGS and Medication Guide.

MORE TO EXPLORE

ASK A CARDIOLOGIST

Dr. Nayak explains the importance of coming to your doctor with questions.

Dr. Nayak was compensated for his time and expenses.

How ELIQUIS Works

View a video explaining how ELIQUIS works to help reduce risk of blood clots and stroke.

SAVINGS AND SUPPORT

Learn about the ELIQUIS Co-pay Card and Free Trial Offer, and sign up for ELIQUIS 360 Support.

− Click to Collapse

Important facts about
ELIQUIS^® (apixaban) This is a summary of important safety information that you need
to know about ELIQUIS.

Look out for the following
icons as
you read:

Talk to your
healthcare team

Call a healthcare
provider right away

Helpful information
to remember

Do not stop taking ELIQUIS without talking to the doctor who prescribed it to you For patients taking ELIQUIS for atrial fibrillation: stopping
ELIQUIS increases your risk of having a stroke.

Talk to your healthcare team before any medical procedures. ELIQUIS may need to be stopped before surgery or a
medical or dental procedure. Your doctor will tell you when you should stop taking ELIQUIS and when you may start
taking it again.
If you have to stop taking ELIQUIS, your doctor may prescribe another medicine to help prevent a blood
clot from forming.

What are the possible serious side effects of ELIQUIS? This is a list of some of the serious side effects of ELIQUIS.

Bleeding

ELIQUIS can cause bleeding, which can be serious, and rarely may lead to death. This is because ELIQUIS is a blood thinner medicine that reduces blood clotting. While taking ELIQUIS, you may bruise more easily and it may take longer than usual for any bleeding to stop.

You may have a higher risk of bleeding if you take ELIQUIS with other medicines that increase your risk of bleeding, such as:

Aspirin
Nonsteroidal anti-inflammatory
drugs (called NSAIDs)
Warfarin

Heparin
Selective serotonin reuptake
inhibitors (SSRIs) or serotonin
norepinephrine reuptake
inhibitors (SNRIs)

Other medicines to help prevent
or treat blood clots

Tell your doctor if you take any of these medicines.

Call your doctor or get medical help right away if you have any of these signs or symptoms of bleeding when taking ELIQUIS:

Unexpected bleeding or bleeding

that lasts a long time, such as:
- Unusual bleeding from
  the gums
- Nosebleeds that
  happen often
- Menstrual or vaginal
  bleeding
  that is heavier
  than normal

Bleeding that is severe or you cannot control
Red, pink, or brown urine
Red or black stools
(looks like tar)
Coughing up or vomiting blood

Vomit that looks like coffee grounds
Unexpected pain, swelling, or joint pain
Headaches
Feeling dizzy or weak

Spinal or epidural blood clots (hematoma)

People who take ELIQUIS, and have
medicine injected into their spinal or
epidural area, or have a spinal puncture,
have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis).

Your risk of developing a spinal or epidural blood clot is higher if:

A thin tube called an epidural catheter
is placed in your back
to
give you
certain medicine

You take NSAIDs or a medicine
to
prevent blood from clotting
You have a history of difficult or repeated epidural or spinal punctures

You have a history of problems with
your spine or have had surgery on
your spine

If you take ELIQUIS and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots or bleeding.

Tell your doctor right away if you have any of these signs or symptoms (especially in your legs and feet) when taking ELIQUIS:

Tingling

Numbness

Muscle weakness

A reaction to ELIQUIS itself

A reaction to ELIQUIS can cause hives, rash, itching, and possibly trouble breathing. If you get this reaction, it will usually happen soon after you take a dose of ELIQUIS.

Get medical help right away if you have any of the following symptoms:

Sudden chest pain or
chest tightness

Sudden swelling of your face
or
tongue
Trouble breathing

Wheezing
Feeling dizzy or faint

Talk to your doctor about any side effect that may be bothering you or that does not go away. These are not all of the possible side effects of ELIQUIS. Call your doctor for medical advice about side effects.

You are encouraged to report any side effects to the FDA at 1-800-FDA-1088. 1-800-FDA-1088.

Who should not take ELIQUIS?

ELIQUIS is not for patients who:

have artificial heart valves

have antiphospholipid syndrome (APS),
especially with positive
triple antibody testing, who have
a history of blood clots

currently have certain types of abnormal bleeding
have had a serious allergic reaction
to ELIQUIS

What should I discuss with my healthcare team before starting ELIQUIS?

Talk to your healthcare team about the following:

Kidney or liver problems

If you have antiphospholipid
syndrome
Any other medical conditions

If you have ever had
bleeding problems

Tell your doctor if you are pregnant or breastfeeding, or planning to become pregnant or breastfeed. You and your doctor should decide if you will take ELIQUIS or breastfeed. You should not do both.

Females who are able to become pregnant: talk with your healthcare provider about pregnancy planning, and your risk of severe uterine bleeding if you are treated with blood thinner medicines, including ELIQUIS.

Tell your healthcare team about all the medicines you take, including any:

prescription medicines

over-the-counter medicines
vitamins

herbal supplements

During treatment, make sure you talk to your healthcare team before you begin to take any new medication.

How should I take ELIQUIS?

Take ELIQUIS exactly as prescribed by your doctor.

Twice daily

With or without food

Do not change your dose or stop taking ELIQUIS unless your doctor tells you to.

What if I miss a dose of ELIQUIS?

If you miss a dose of ELIQUIS, take it as soon as you remember, and do not take more than one dose at the same time.

When should I refill my prescription?

If you are taking ELIQUIS for atrial fibrillation, stopping ELIQUIS may increase your risk of having a stroke. Do not
run out of ELIQUIS. Refill your prescription before
you run out. When leaving the hospital following hip or knee replacement, be sure that
you will have ELIQUIS available to avoid missing any doses.

ELIQUIS is available in two different tablets. Your doctor or healthcare provider will determine what dose is right for you.

2.5 mg tablet

Round, with a pale yellow color

5 mg tablet

Oval, with a pale orange or pink color

Note: Images do not represent actual tablet size.

On one side of each tablet, there is a number indicating the dosage
strength of the tablet (in milligrams).
On the other side, there is a
medication identification number.

What is ELIQUIS?
ELIQUIS is a prescription medicine used to:

Reduce the risk of stroke and
blood clots in people who have
atrial fibrillation (AFib),
a type
of irregular heartbeat,
not
caused by a heart valve
problem.

Treat blood clots in the
veins of the legs (deep vein
thrombosis – DVT) or lungs
(pulmonary embolism – PE),
and
reduce the risk of them
occurring again.

Reduce the risk of forming a
blood clot in the legs (DVT)
and lungs (PE) of people who
have just had hip or knee replacement surgery.

Please see U.S. Full Prescribing Information, including Boxed WARNINGS and Medication Guide.

The product information provided in this
site is intended only for residents of the
United States. The products discussed herein may have different product labeling in
different countries.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with
a healthcare provider. All decisions
regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. 1-800-FDA-1088.

+ More Important Safety Information

SELECTED IMPORTANT SAFETY INFORMATION & INDICATIONS

ELIQUIS may need to be stopped prior to surgery or a medical or dental procedure. Your doctor will tell you when you should stop
taking ELIQUIS and when you may start taking it again. If you have to stop taking ELIQUIS, your doctor may prescribe another
medicine to help prevent a blood clot from forming.

ELIQUIS can cause bleeding, which can be serious, and rarely may lead to death. This is because ELIQUIS is a blood thinner
medicine that reduces blood clotting.

You may have a higher risk of bleeding if you take ELIQUIS and take other medicines that increase your risk of bleeding, such as
aspirin, nonsteroidal anti-inflammatory drugs (called NSAIDs), warfarin (COUMADIN^®), heparin, selective serotonin reuptake
inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), and other medicines to help prevent or treat blood clots.
Tell your doctor about all of the medicines you take, including any over-the-counter medicines, vitamins, and herbal supplements.

AFib Not Caused by
a Heart Valve Problem

DVT/PE

Hip or Knee
Replacement Surgery

ELIQUIS^® and the ELIQUIS logo are trademarks
of Bristol-Myers Squibb Company.

All other trademarks are property of their
respective companies.

ELIQUIS^® (apixaban)

Please see U.S. Full Prescribing Information, including Boxed WARNINGS and Medication Guide.

IMPORTANT SAFETY INFORMATION & INDICATIONS

For people taking ELIQUIS (apixaban) for atrial fibrillation: Do not stop taking ELIQUIS
without talking to the doctor who prescribed it for you. Stopping ELIQUIS increases your risk
of having a stroke.

ELIQUIS may need to be stopped prior
to surgery or a medical or dental
procedure. Your doctor will
tell you
when you should stop taking ELIQUIS
and when you may start taking it again.
If you have
to stop taking ELIQUIS, your
doctor may prescribe another medicine
to help prevent a blood clot
from forming.

ELIQUIS can cause bleeding, which
can be serious, and rarely may lead to death. This is because
ELIQUIS is a blood thinner medicine that reduces blood clotting.

You may have a higher risk of
bleeding if you take ELIQUIS and take other medicines that
increase your risk of bleeding, such as aspirin, nonsteroidal anti-inflammatory drugs (called
NSAIDs), warfarin, heparin, selective serotonin reuptake inhibitors (SSRIs) or serotonin
norepinephrine reuptake inhibitors (SNRIs), and other medicines to help prevent or treat
blood clots. Tell your doctor about all of the medicines you take, including any over-the-counter
medicines, vitamins, and herbal supplements.

While taking ELIQUIS, you may bruise more easily and it may take longer
than usual for any
bleeding to stop.

Call your doctor or get medical help right away if you have any of these signs or symptoms of
bleeding when taking ELIQUIS:

unexpected bleeding or bleeding that lasts a long time, such as unusual bleeding from the
gums, nosebleeds that happen often, or menstrual or vaginal bleeding that is heavier
than normal
bleeding that is severe or you cannot control
red, pink, or brown urine; red or black stools (looks like tar)
coughing up or vomiting blood or vomit that looks like coffee grounds
unexpected pain, swelling, or
joint pain
headaches, or feeling dizzy or weak

ELIQUIS (apixaban) is not for patients with artificial heart valves.

Spinal or epidural blood clots (hematoma). People who take ELIQUIS, and have medicine injected
into their spinal and epidural area, or have a spinal puncture have a risk of forming
a blood clot
that can cause long-term
or permanent loss of the ability to
move (paralysis). Your risk of
developing a spinal or epidural blood
clot is higher if:

a thin tube called an epidural catheter is placed in your back to give you certain medicine
you take NSAIDs or a medicine to prevent blood from clotting
you have a history of difficult or repeated epidural or spinal punctures
you have a history of problems with your spine or have had surgery on your spine

If you take ELIQUIS and receive spinal anesthesia or have a spinal puncture, your doctor should
watch you closely
for symptoms of spinal or epidural
blood clots or bleeding. Tell your doctor
right
away if you have tingling,
numbness, or muscle weakness,
especially in your legs and feet.

ELIQUIS is not for use in people with antiphospholipid syndrome (APS), especially with positive
triple antibody testing, who have a history of blood clots.

Do not take ELIQUIS if you currently have certain types of abnormal
bleeding or have had a
serious allergic
reaction to ELIQUIS.

Before you take ELIQUIS, tell your doctor if you have kidney or liver problems, have
antiphospholipid syndrome, have any other medical condition, or have ever had bleeding problems.
Tell your doctor if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed.
You
and your doctor should decide if you
will take ELIQUIS or breastfeed. You
should not do both. Females who are able to become pregnant: talk with your healthcare provider about pregnancy planning, and your risk of severe uterine bleeding if you are treated with blood thinner medicines, including ELIQUIS.

Take ELIQUIS exactly as prescribed
by your doctor. Take ELIQUIS twice
every day with or without
food, and do
not change your dose or stop taking it
unless your doctor tells you to. If you
miss a
dose of ELIQUIS, take it as soon
as you remember, and do not take
more than one dose at the same
time.
If you are taking ELIQUIS for atrial
fibrillation, stopping ELIQUIS may
increase your risk
of having a stroke.
Do not run out of ELIQUIS. Refill your
prescription before you run out.
When
leaving the hospital following
hip or knee replacement, be sure that
you will have ELIQUIS
available to avoid
missing any doses.

Possible serious side effects include bleeding or a reaction to ELIQUIS itself. A reaction to
ELIQUIS can cause hives, rash, itching, and possibly
trouble breathing. If you get this
reaction, it
will usually happen soon
after you take a dose of ELIQUIS. Get
medical help right away if you have
sudden chest pain or chest tightness,
have sudden swelling of your face or
tongue, have trouble
breathing,
wheezing, or feeling dizzy or faint.

INDICATIONS

ELIQUIS (apixaban) is a prescription medicine used to reduce the risk of stroke and blood clots in
people who have atrial fibrillation, a type of
irregular heartbeat, not caused by a
heart valve
problem.

ELIQUIS is a prescription medicine used to treat blood clots in the veins of your legs (deep vein
thrombosis) or lungs (pulmonary embolism), and reduce the risk of them occurring again.

ELIQUIS is a prescription medicine used to reduce the risk of forming a blood clot in the legs and
lungs of people
who have just had hip or knee
replacement surgery.

Please see U.S. Full Prescribing Information, including Boxed WARNINGS and Medication Guide.

ELIQUIS is available in 2.5-mg and
5-mg tablets.

LOVENOX^® is a registered trademark of Aventis Pharma S.A.

All other trademarks are
property of their respective companies.

The product information provided in
this site is intended only for residents
of the United States.
The products
discussed herein may have different
product labeling in different countries.

The health information contained
herein is provided for educational
purposes only and is not
intended to
replace discussions with a healthcare
provider. All decisions regarding patient
care
must be made with a healthcare
provider, considering the unique
characteristics of the patient.

You are encouraged to report negative
side effects of prescription drugs to
the FDA. Visit
www.fda.gov/medwatch, or call
1-800-FDA-1088. 1-800-FDA-1088.

Co-pay Card

ELIGIBILITY REQUIREMENTS:

You may be eligible for the Co-pay Card for ELIQUIS^® (apixaban) if:

You are insured by commercial insurance and your prescription insurance coverage does not cover the full cost of your prescription, that is, you have a co-pay obligation for ELIQUIS;
You do not have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), or Department of Defense (DOD)
programs; patients who move from commercial plans to state or federal healthcare programs will no longer
be eligible;
You are 18 years of age or older; and
You are a resident of the United States, Puerto Rico, or other select U.S. Territory.

TERMS OF USE:

Eligible patients who present
an activated Co-pay Card together with
a valid prescription for ELIQUIS at participating pharmacies may pay as little as $10 per 30-day supply (up
to
74 tablets for the first fill and up to
60 tablets for all subsequent fills) for
up to 24 months, subject to a
maximum annual benefit of $6,400.
Other restrictions may apply. Patient is
responsible for applicable taxes, if any.
Offer not applicable to co-pays of
$10 or less.
Patients, pharmacists, and prescribers
cannot seek reimbursement, from
health insurance or any third party, for
any part of the benefit received by the
patient through this offer.
Your acceptance of this offer confirms
that this offer is consistent with your
insurance and that you will report the
value received as may be required by
your insurance provider.
Card must be activated before use. Activation and first use of the Co-pay
Card must take place by December 31,
2024. Card expires 24 months from
activation. Upon expiration, eligible
patients may re-enroll in the Co-pay
Card Program.
All Program payments are for the benefit of the patient only.
Only valid in the United States, Puerto Rico, and other select U.S. Territories; this offer is void where restricted or prohibited by law.
This offer is non-transferable, no substitutions are permissible, and offer cannot be combined with any other rebate/coupon, free trial, or similar
offer for the specified prescription.
The Co-pay Card may not be sold, purchased, traded, or counterfeited. Reproductions of this Co-pay Card
are
void.
Bristol-Myers Squibb and Pfizer reserve the right to rescind, revoke, or amend
this offer at any time without notice.
This offer is not conditioned on
any past, present, or future purchase,
including refills.
No membership fees.
The Co-pay Card for ELIQUIS
is not health insurance. The Co-pay Card will be accepted only
at participating pharmacies. For
those
customers using mail order or
any
non-participating retail
pharmacy,
please call 866-279-4730
to request
a patient rebate form, or
go to www.patientrebateonline.com to
download a form.

Questions can also be submitted via
mail to:

P.O. Box 2914
Phoenix, AZ, 85062-2914.

BY USING THIS CARD, YOU AND YOUR PHARMACIST UNDERSTAND AND AGREE
TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.

To the pharmacist: For processing assistance, please call McKesson
Pharmacy Support at 1-866-279-4730.

Please see Full Prescribing Information, including Boxed WARNINGS and Medication Guide.

Free 30-Day Trial Offer

ELIGIBILITY REQUIREMENTS:

You may be eligible for the Free 30-Day
Trial Offer for ELIQUIS^® (apixaban) if:

You have not previously filled
a prescription for ELIQUIS;
You have a valid 30-day prescription
for ELIQUIS;
You are being treated with ELIQUIS
for
an FDA-approved indication that
an
HCP has planned for more than
35 days of treatment;
You are 18 years of age, or older; and
You are a resident of the United States, Puerto Rico, or other select U.S. Territory.

TERMS OF USE:

Eligible patients who present a Free
30-Day Trial card together with a
valid
30-day prescription for ELIQUIS
at
participating pharmacies can
receive a
free 30-day supply (up to
74 tablets) of
ELIQUIS. Patient is
responsible for
applicable taxes, if
any. This offer may
not be redeemed
on prescriptions
written for longer
than 30 days.
This offer is limited to one use per
patient per lifetime and is
non-transferable. By redeeming
this offer, you certify that you
have not
previously filled
a prescription for ELIQUIS.
The Free 30-Day Trial for the
specified
prescription cannot be
combined with
any other
rebate/coupon, free trial,
or similar
offer. No substitutions
are permitted.
Patients, pharmacists, and
prescribers
cannot seek
reimbursement for
the Free 30-Day
Trial of ELIQUIS from
health
insurance or any third party,
including state or federally
funded
programs.
Patients may not count the Free
30-Day Trial of ELIQUIS as an
expense
incurred for purposes of
determining
out-of-pocket costs for
any plan,
including true
out-of-pocket
costs, (TrOOP), for
purposes of calculating the
out-of-pocket threshold
for Medicare
Part D plans.
Activation and use of the Free
30-Day Trial card must take place by
December 31, 2024. This card
expires
on December 31, 2024.
Only valid in the United States, Puerto Rico, and other select U.S. Territories; this offer is void where restricted or prohibited by law.
Bristol-Myers Squibb and Pfizer
reserve
the right to rescind, revoke,
or amend
this offer at any time
without notice.
This Free 30-Day Trial card may
not
be sold, purchased, traded, or
counterfeited. Reproductions of
this card are void.
This offer is not conditioned on any
past, present, or future purchase,
including refills.
The ELIQUIS Free 30-Day Trial offer
is not health insurance.

BY USING THIS CARD, YOU AND YOUR PHARMACIST UNDERSTAND AND
AGREE
TO COMPLY WITH THESE
ELIGIBILITY REQUIREMENTS AND
TERMS OF USE.

To the pharmacist: For processing
assistance, please call McKesson
Pharmacy Support at 1-866-279-4730.

Please see Full Prescribing Information, including Boxed WARNINGS and Medication Guide.

Considering ELIQUIS

ELIQUIS IS FDA-APPROVED

ELIQUIS WAS PROVEN BETTER THAN WARFARIN:

BASED ON EXTENSIVE CLINICAL RESEARCH

ELIQUIS WAS PROVEN EFFECTIVE

TRIAL 1

TRIAL 2

More Reasons to Consider ELIQUIS

MORE TO EXPLORE

ASK A CARDIOLOGIST

How ELIQUIS Works

SAVINGS AND SUPPORT

Important facts about ELIQUIS® (apixaban) This is a summary of important safety information that you need to know about ELIQUIS.

SELECTED IMPORTANT SAFETY INFORMATION & INDICATIONS

AFib Not Caused by a Heart Valve Problem

DVT/PE

Hip or Knee Replacement Surgery

You Are Leaving This Site

You Are Leaving This Site

You Are Leaving This Site

Learn More and Activate Your Co-pay* Card

Select document to view or download

ELIQUIS® (apixaban)

IMPORTANT SAFETY INFORMATION & INDICATIONS

INDICATIONS

Co-pay Card

ELIGIBILITY REQUIREMENTS:

TERMS OF USE:

Free 30-Day Trial Offer

ELIGIBILITY REQUIREMENTS:

TERMS OF USE:

Terms and Conditions

Sure You Want to Leave?

ELIQUIS IS
FDA-APPROVED

Important facts about
ELIQUIS^® (apixaban) This is a summary of important safety information that you need
to know about ELIQUIS.

AFib Not Caused by
a Heart Valve Problem

Hip or Knee
Replacement Surgery

You Are Leaving
This Site

You Are Leaving
This Site

You Are Leaving
This Site

ELIQUIS^® (apixaban)